Cancer is the unrestrained expansion of tumor cells anywhere in the body and screening is a means of perceiving disease early in asymptomatic people. There are different types of cancer for instance breast cancer, lung cancer, skin cancer, colon cancer, prostate cancer, and others. Some of the essential characteristics include sensitivity & specificity and reliability & precise. In addition, some of the risks associated with cancer screening overtreatment are overdiagnosis, false positive test results and false negative tests results etc.
Several technologies and methods have facades for screening cancer at an early phase. Some of the tests such as imaging tests, biopsy tests, laboratory tests, endoscopy tests, and genomic tests are involved in cancer screening. Imaging tests include ultrasound, tomography, mammograms, and MRI etc. Endoscopy test includes endoscopic retrograde & cholangiopancreatography (ERCP) and endoscopic ultrasound. Additionally, genomic tests include Oncotype test, MammaPrint test, mammostrat test, breast cancer index test and PAM50 test.
According to the study, “Asia Pacific Cancer Screening Market (2018-2023)” some of the major companies are currently working in the Asia Pacific cancer screening market are Hoffman La Roche Ltd, Johnson & JohnsonPvt Ltd., Roche Molecular Systems Inc., Merck & Co., Thermo Fisher Scientific Inc.,Philips Inc.,ARUP Laboratories Inc., Bayer AG,Dako Inc., BioMerieux Inc.,Ventana Medical Systems Inc., GlaxoSmithKline PLC, Myriad Genetics Inc., Leica Biosystems Nussloch GmbH, Quest Diagnostics Incorporated, Biogenex Laboratories, Inc., Qiagen Ltd., Abbott diagnostics, Hologic Inc., GE Healthcare, Siemens Healthcare GmbH, Pfizer.
The key technologies used in cancer screening are molecular diagnostics and immune histochemistry. The molecular diagnostic is classified by real-time PCR, in-situ hybridization and gene sequencing. Moreover, some indications are cardiovascular diseases, virology diseases, inflammation & autoimmune diseases, oncology, and central nervous system disorders. Oncology tests include lung cancer, mouth cancer, bone cancer, eye cancer, breast cancer, abdominal cancer, gastric cancer, colorectal cancer, and melanoma cancer etc.
In India, this market is rapidly increasing with some opportunities to focus on easier business conditions and tax regime. There are 1 million cases of cancer diagnosed annually an amount to be enhanced by 5 billion adding opportunities to screen cancer detection encounter human and economic costs from the increasing rate of cancer detection.
The market of the Asia-Pacific region is generally driven by rising in the number of cancer cases, followed by growing awareness among individuals, development in Low Dose Computed Tomography (LDCT) technology, enhanced procedure accuracy, increasing screening programs, more sedentary lifestyle (consumption of diets rich in fats, sugars, &salts and lack of physical exercise), favorable regulatory framework, growing levels of population, growing patient pool, increasing innovative technologies & methodologies and government-centered initiatives etc. Additionally, some of the restraints factors are rigorous regulations, lack of screening guidelines, the high cost of screening tests, regional trade barriers and transparency in medicinal treatments and many others.
During 2018-2023, the market is expected to grow at a CAGR of 17.3% consequential in annual proceeds of US$ 32.2 billion. In the coming years market is expected to grow fast owing to the growing adoption of high scale investment on diagnostic devices.
To know more, click on the link below:-
Related Reports:-
https://www.kenresearch.com/healthcare/medical-devices/mea-cancer-screening-2018-2023/172428-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
